UNSPSC 51294906: Pizotifen or pizotyline

This classification denotes a serotonin antagonist with the molecular formula C19H21NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0BY8440V3N, chemically known as 4-(9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2-b)thien-4-ylidene)-1-methylpiperidine but generally known as pizotifen, which bears US NIH Compound Identifier 27400. European Medicines Agency schedules Pizotifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09954MIG. The term PIZOTIFEN is an International Non-Proprietary Name.

UNSPSC 51294906 Pizotifen or pizotyline is a Commodity code nominally identifying a specific migraine-preventive pharmaceutical, but recent state and local opportunities tagged under this code do not reflect purchases of pizotifen itself. Instead, the recent solicitations show state and local procurement activity focused on naloxone (opioid-overdose reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription program infrastructure. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing contracts for generic pharmaceuticals and OTC products through an RFP; and the Texas Health and Human Services Commission is gathering market intelligence on direct-to-manufacturer prescription capabilities through an RFI.

Geographic activity spans Florida, Minnesota (with Oregon as a participating member of MMCAP), and Texas. The representative recent opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The code shows little relevant recent activity in pizotifen specifically; the opportunities are misaligned with the Commodity's stated scope and reflect broader pharmaceutical procurement across diverse product categories and delivery models rather than migraine prevention therapeutics.